| abstract |
Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF[beta] and/or LTBP3-TGF[beta]. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF[beta] activation, and treating subjects suffering from TGF[beta]-related disorders, such as fibrotic conditions. Methods of selecting a context- dependent or context-independent isoform-specific TGF[beta] inhibitor for a subject in need thereof are also provided. |